Table 4.

Adjusteda ORs (95% CI) of the association between CLL diagnosis and statin use, excluding the year before the index date, by statin subgroup according to period, duration, and dose

Statin useHydrophilicHigh-potency lipophilicLow-potency lipophilic
Time of first use (years prior to the index date)b
 2–51.07 (0.79–1.44)0.96 (0.77–1.19)0.62 (0.28–1.40)
 6–100.93 (0.64–1.34)0.90 (0.71–1.14)0.61 (0.33–1.12)
 11+1.42 (0.90–2.24)0.96 (0.69–1.34)0.65 (0.39–1.11)
Relative duration (fraction of drug history)b
 1%–25%1.03 (0.79–1.33)0.91 (0.74–1.12)0.69 (0.43–1.12)
 26%–50%1.10 (0.68–1.77)0.85 (0.64–1.13)0.56 (0.22–1.43)
 51%–75%1.60 (0.84–3.04)1.10 (0.76–1.59)0.70 (0.29–1.68)
 ≥76%0.99 (0.34–2.91)1.40 (0.81–2.41)0.42 (0.15–1.17)
Continuous useb
 <12 months1.00 (0.77–1.30)0.97 (0.80–1.18)0.65 (0.43–1.01)
 ≥12 months1.23 (0.85–1.78)0.90 (0.70–1.15)0.60 (0.32–1.14)
Duration (months)b
 1–60.91 (0.60–1.40)0.95 (0.70–1.29)0.41 (0.16–1.06)
 7–241.06 (0.73–1.52)0.85 (0.63–1.13)0.81 (0.43–1.52)
 25–481.04 (0.65–1.67)1.00 (0.75–1.34)0.60 (0.27–1.32)
 ≥491.39 (0.93–2.09)0.97 (0.75–1.26)0.67 (0.36–1.23)
Cumulative dose (DDD)b
 1–1200.87 (0.53–1.42)0.92 (0.67–1.25)0.68 (0.34–1.35)
 121–4800.87 (0.56–1.33)0.92 (0.70–1.22)0.71 (0.37–1.35)
 481–1,2001.39 (0.93–2.07)0.97 (0.73–1.29)0.71 (0.35–1.44)
 ≥1,2011.18 (0.83–1.70)0.94 (0.72–1.23)0.47 (0.20–1.09)
Average annual dose (DDD/year)b
 1–1802.81 (0.83–9.50)0.97 (0.65–1.43)0.74 (0.47–1.16)
 181–3651.46 (0.96–2.22)0.96 (0.79–1.17)0.44 (0.22–0.88)
 ≥3660.96 (0.74–1.23)0.89 (0.68–1.15)0.88 (0.30–2.58)
  • Abbreviation: DDD, defined daily dose.

  • aAdjusted for the matching variables (age, gender, residence, and duration of coverage), chronic cardiovascular disease (excluding hypertension), income quintile, number of physician visits 5 years before index date, ever-use of non-statin lipid-lowering drugs, non-aspirin NSAIDs, aspirin, and derivatives, and other statin subgroups.

  • bCompared with never use of the specific statin subgroup.